Cargando…
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with...
Autores principales: | Ngwe Tun, Mya Myat, Sakura, Takaya, Sakurai, Yasuteru, Kurosaki, Yohei, Inaoka, Daniel Ken, Shioda, Norifumi, Smith, Chris, Yasuda, Jiro, Morita, Kouichi, Kita, Kiyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043503/ https://www.ncbi.nlm.nih.gov/pubmed/35477500 http://dx.doi.org/10.1186/s41182-022-00422-7 |
Ejemplares similares
-
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2022) -
5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
por: Sakurai, Yasuteru, et al.
Publicado: (2021) -
The Antiviral Effect of the Chemical Compounds Targeting DED/EDh Motifs of the Viral Proteins on Lymphocytic Choriomeningitis Virus and SARS-CoV-2
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2021) -
Persistence of Neutralizing Antibody Against Dengue Virus 2 After 70 Years from Infection in Nagasaki
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2016) -
Ending tuberculosis by 2030: understanding the transmission
por: Pandey, Basu Dev, et al.
Publicado: (2023)